NHSGGC : NHS Greater Glasgow and Clyde - Homepage of our ...



[pic] [pic] [pic]

This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in this area.

Sections can include:

• Combined Modality Therapies

• Drug & Biological Therapies

• Pathology, Staging, Polymorphisms & Biomarkers

• Prognosis, Survival & Risk Factors

• Radiotherapy & Imaging

• Stem Cell Transplantation

• Supportive Care & Symptom Management

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by:

Kirsty Coltart

Subject Librarian

Beatson West of Scotland Cancer Centre

0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk

General

Annibali, O., Sabatino, F., Mantelli, F., et al. (2016). Mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment. Critical Reviews in Oncology-Hematology 100,37-45.

Ansell, S.M. (2016). Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology 91,4:434-442.

Bassan, R., Maino, E. and Cortelazzo, S. (2016). Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. European journal of haematology 96,5:447-460.

BCSH. Guidelines for the management of diffuse large b-cell lymphoma (May 2016)

Cheah, C.Y., Seymour, J.F. and Wang, M.L. (2016). Mantle Cell Lymphoma. Journal of Clinical Oncology 34,11:1256-1269.

Chen, R., Sanchez, J. and Rosen, S.T. (2016). Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) 30,4:353-360.

Guffey Johnson, J., Terpak, L.A., Margo, C.E., et al. (2016). Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa. Cancer Control 23,2:140-149.

Jacobson, C.A. and Freedman, A.S. (2016). Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Current Hematologic Malignancy Reports 11,3:218-223.

Kahl, B.S. and Yang, D.T. (2016). Follicular lymphoma: evolving therapeutic strategies. Blood 127,17:2055-2063.

Kheterpal, M., Mehta-Shah, N., Virmani, P., et al. (2016). Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Current Hematologic Malignancy Reports 11,3:224-233.

Landsburg, D.J. (2016). Management of Patients with MYC-Altered Lymphomas. Current Hematologic Malignancy Reports 11,3:208-217.

Lightner, A.L., Shannon, E., Gibbons, M.M., et al. (2016). Primary Gastrointestinal Non-Hodgkin's Lymphoma of the Small and Large Intestines: a Systematic Review. Journal of Gastrointestinal Surgery 20,4:827-839.

NICE. NG47 Haematological cancers: improving outcomes (May 2016)

Ruan, J. and Martin, P. (2016). Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Current Hematologic Malignancy Reports 11,3:234-240.

Witmer, M.T. (2016). Primary Vitreoretinal Lymphoma: Management of Isolated Ocular Disease. Cancer Control 23,2:110-116.

Zhang, Y., Xu, W., Liu, H., et al. (2016). Therapeutic options in peripheral T cell lymphoma. Journal of hematology & oncology 9,37.

Combined Modality Therapies

El-Asmar, J., Reljic, T., Ayala, E., et al. (2016). Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biology of Blood & Marrow Transplantation 22,5:802-814.

Federico, M., Luminari, S., Pellegrini, C., et al. (2016). Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica 101,4:e139-41.

Glass, J., Won, M., Schultz, C.J., et al. (2016). Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology 34,14:1620-1625.

Illidge, T.M., McKenzie, H.S., Mayes, S., et al. (2016). Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. British journal of haematology 173,2:274-282.

Ruella, M., Filippi, A.R., Bruna, R., et al. (2016). Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International journal of radiation oncology, biology, physics 94,4:783-791.

Drug & Biological Therapies

Armand, P., Kim, H.T., Sainvil, M., et al. (2016). The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. British journal of haematology 173,1:96-104.

Armand, P., Redd, R., Bsat, J., et al. (2016). A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. British journal of haematology 173,1:89-95.

Boll, B., Goergen, H., Behringer, K., et al. (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127,18:2189-2192.

Burke, J.M., van der Jagt,Richard H C., Kahl, B.S., et al. (2016). Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clinical lymphoma, myeloma & leukemia 16,4:182-190.e1.

Cheah, C.Y., Chihara, D., Ahmed, M., et al. (2016). Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology 27,5:895-901.

Coleman, M., Lammers, P.E., Ciceri, F., et al. (2016). Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia 16,4:175-181.

Dada, R., Zekri, J. and Al Saadi, R. (2016). Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opinion on Biological Therapy 16,6:739-745.

Devata, S. and Wilcox, R.A. (2016). Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. American Journal of Clinical Dermatology 17,3:225-237.

Fajardo, S., Zook, F. and Dotson, E. (2016). Specialty pharmacy for hematologic malignancies. American Journal of Health-System Pharmacy 73,11:797-809.

Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., et al. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet Haematology 3,5:e217-27.

Goldschmidt, N., Kleinstern, G., Orevi, M., et al. (2016). Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Cancer Chemotherapy & Pharmacology 77,5:1053-1060.

Jalali, A., Ha, F.J., Chong, G., et al. (2016). Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Annals of Hematology 95,5:809-816.

Jo, J., Baek, J.H., Lee, J., et al. (2016). Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. Asia-Pacific Journal of Clinical Oncology 12,2:159-166.

Khan, O.S., Bhat, A.A., Krishnankutty, R., et al. (2016). Therapeutic Potential of Resveratrol in Lymphoid Malignancies. Nutrition & Cancer 68,3:365-373.

Kim, S.J., Shin, D., Kim, J.S., et al. (2016). A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Annals of Oncology 27,4:712-718.

Korfel, A., Schlegel, U., Herrlinger, U., et al. (2016). Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. Journal of Clinical Oncology 34,15:1757-1763.

Lipowska-Bhalla, G., Fagnano, E., Illidge, T.M., et al. (2016). Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia & lymphoma 57,6:1269-1280.

Matsuki, E. and Younes, A. (2016). Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Current Treatment Options in Oncology 17,6:31.

Oh, S.Y., Kim, W.S., Kim, J.S., et al. (2016). A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia & lymphoma 57,6:1406-1412.

Pellegrini, C., Dodero, A., Chiappella, A., et al. (2016). A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Journal of hematology & oncology 9,38.

Penalver, F.J., Delgado, J., Loscertales, J., et al. (2016). Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. European journal of haematology 96,5:532-540.

Shin, D., Kim, S.J., Yoon, D.H., et al. (2016). Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemotherapy & Pharmacology 77,4:865-873.

Trneny, M., Lamy, T., Walewski, J., et al. (2016). Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncology 17,3:319-331.

Pathology, Staging, Polymorphisms & Biomarkers

Arcaini, L., Rossi, D. and Paulli, M. (2016). Splenic marginal zone lymphoma: from genetics to management. Blood 127,17:2072-2081.

Behdad, A. and Bailey, N.G. (2016). Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. Surgical pathology clinics 9,1:41-54.

Giulino-Roth, L. and Goldman, S. (2016). Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. British journal of haematology 173,4:531-544.

Iqbal, J., Naushad, H., Bi, C., et al. (2016). Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?. Blood reviews 30,2:73-88.

Iqbal, J., Wilcox, R., Naushad, H., et al. (2016). Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?. Blood reviews 30,2:89-100.

La Nasa, G., Greco, M., Littera, R., et al. (2016). The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. Journal of hematology & oncology 9,26.

Zucca, E. and Bertoni, F. (2016). The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood 127,17:2082-2092.

Prognosis, Survival & Risk Factors

Jakobsen, L.H., Hutchings, M., de Nully Brown, P., et al. (2016). No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. British journal of haematology 173,2:236-244.

Kim, M.M., Dabaja, B.S., Medeiros, J., et al. (2016). Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. American Journal of Clinical Oncology 39,2:109-113.

Sasse, S., Alram, M., Muller, H., et al. (2016). Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leukemia & lymphoma 57,5:1067-1073.

Radiotherapy & Imaging

Adams, H.J.A. and Kwee, T.C. (2016). Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Annals of Hematology 95,5:695-706.

Barrington, S.F., Kirkwood, A.A., Franceschetto, A., et al. (2016). PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 127,12:1531-1538.

Barrington, S.F. and Mikhaeel, N.G. (2016). PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Current Hematologic Malignancy Reports 11,3:185-195.

Bathla, G. and Hegde, A. (2016). Lymphomatous involvement of the central nervous system. Clinical radiology 71,6:602-609.

Coyle, M., Kostakoglu, L. and Evens, A.M. (2016). The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Therapeutic Advances in Hematology 7,2:108-125.

Zinzani, P.L., Broccoli, A., Gioia, D.M., et al. (2016). Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. Journal of Clinical Oncology 34,12:1376-1385.

Special Populations

Cairo, M.S. and Pinkerton, R. (2016). Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. British journal of haematology 173,4:507-530.

Castillo, J.J., Beltran, B.E., Miranda, R.N., et al. (2016). EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology 91,5:529-537.

Galardy, P.J., Bedekovics, T. and Hermiston, M.L. (2016). Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. British journal of haematology 173,4:625-636.

Michaux, K., Bergeron, C., Gandemer, V., et al. (2016). Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols. Pediatric Blood & Cancer 63,7:1214-1221.

Pillai, V., Tallarico, M., Bishop, M.R., et al. (2016). Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. British journal of haematology 173,4:573-581.

Sickinger, M.T., von Tresckow, B., Kobe, C., et al. (2016). PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis. Critical Reviews in Oncology-Hematology 101,86-92.

Turner, S.D., Lamant, L., Kenner, L., et al. (2016). Anaplastic large cell lymphoma in paediatric and young adult patients. British journal of haematology 173,4:560-572.

Zhou, R., Ng, A., Constine, L.S., et al. (2016). A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials. International journal of radiation oncology, biology, physics 95,2:707-711.

Supportive Care & Symptom Management

Belle, M., Muzzatti, B., Tomas, M., et al. (2016). Psychological screening of onco-hematologic inpatients: Distress Thermometer administration. Tumori 102,2:178-183.

Bryant, J., Mansfield, E., Hall, A., et al. (2016). The psychosocial outcomes of individuals with hematological cancers: Are we doing enough high quality research, and what is it telling us? Critical Reviews in Oncology-Hematology 101,21-31.

Elting, L.S., Xu, Y., Chavez-MacGregor, M., et al. (2016). Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. Supportive Care in Cancer 24,6:2695-2706.

Lyman, G.H., Poniewierski, M.S. and Culakova, E. (2016). Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opinion on Drug Safety 15,4:483-492.

Pettengell, R., Bias, P., Mueller, U., et al. (2016). Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Supportive Care in Cancer 24,6:2677-2684.

Taylor, K., Joske, D., Bulsara, M., et al. (2016). Protocol for Care After Lymphoma (CALy) trial: a phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care. BMJ Open 6,5:e010817.

Weycker, D., Li, X., Barron, R., et al. (2016). Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Supportive Care in Cancer 24,6:2481-2490.

Transplantation

Alinari, L., Gru, A., Quinion, C., et al. (2016). De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. American Journal of Hematology 91,4:395-399.

Bhatt, V.R. (2016). Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports 11,3:196-207.

Brudno, J.N., Somerville, R.P.T., Shi, V., et al. (2016). Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. Journal of Clinical Oncology 34,10:1112-1121.

Ferreri, A.J.M. and Illerhaus, G. (2016). The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 127,13:1642-1649.

Kuruvilla, J. (2016). The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. Blood 127,17:2093-2100.

Rashidi, A., Ebadi, M. and Cashen, A.F. (2016). Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone marrow transplantation 51,4:521-528.

Sibon, D., Morschhauser, F., Resche-Rigon, M., et al. (2016). Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica 101,4:474-481.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin.

Sources used for this bulletin:

OVID MEDLINE, SIGN, NICE and Healthcare Improvement Scotland

-----------------------

Lymphomas

June 2016

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download